An Open-label Phase II Study of Lorvotuzumab Mertansine
Clinical trial NCT02420873 · COMPLETED
Trial details
- NCT number
- NCT02420873
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-12
- Primary completion
- 2017-06-06
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.